45 results
8-K
EX-2.1
IKNA
Ikena Oncology Inc
7 Aug 23
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
8:02am
and in the applicable provisions of the DGCL and the DLLCA.
2.3 Closing; First Effective Time; Second Effective Time. Subject to the satisfaction or waiver … or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant
8-K
EX-3.1
IKNA
Ikena Oncology Inc
7 Aug 23
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
8:02am
in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery … or shall have established to the satisfaction of the Corporation that such tax has been paid.
6.9 Status as Stockholder. Upon each Conversion Date
8-K
EX-10.1
medrzgyvk1159 vuwnhq
7 Aug 23
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
8:02am
8-K
EX-99.3
hrnbg
15 May 23
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
9:09am
8-K
EX-1.1
xnqwek6kuvdb1hyao
15 May 23
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
9:09am
8-K
gougp5y
15 May 23
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
9:09am
424B5
qtt csjfntpugp1q
15 May 23
Prospectus supplement for primary offering
7:27am
S-3
EX-4.5
2yi3 ff22v
27 Apr 22
Shelf registration
5:17pm
S-3
EX-4.6
m83 9k7imryt4wanxm0
27 Apr 22
Shelf registration
5:17pm
S-3
EX-1.2
c9qkwjzxnv gwtm
27 Apr 22
Shelf registration
5:17pm
S-3
r0046
27 Apr 22
Shelf registration
5:17pm
10-K
oj85o oe1tat7z1
17 Mar 22
Annual report
6:31am